An engineered transforming growth factor β (TGF-β) monomer that functions as a dominant negative to block TGF-β signaling

The transforming growth factor β isoforms, TGF-β1, -β2, and -β3, are small secreted homodimeric signaling proteins with essential roles in regulating the adaptive immune system and maintaining the extracellular matrix. However, dysregulation of the TGF-β pathway is responsible for promoting the progression of several human diseases, including cancer and fibrosis. Despite the known importance of TGF-βs in promoting disease progression, no inhibitors have been approved for use in humans. Herein, we describe an engineered TGF-β monomer, lacking the heel helix, a structural motif essential for binding the TGF-β type I receptor (TβRI) but dispensable for binding the other receptor required for TGF-β signaling, the TGF-β type II receptor (TβRII), as an alternative therapeutic modality for blocking TGF-β signaling in humans. As shown through binding studies and crystallography, the engineered monomer retained the same overall structure of native TGF-β monomers and bound TβRII in an identical manner. Cell-based luciferase assays showed that the engineered monomer functioned as a dominant negative to inhibit TGF-β signaling with a Ki of 20–70 nm. Investigation of the mechanism showed that the high affinity of the engineered monomer for TβRII, coupled with its reduced ability to non-covalently dimerize and its inability to bind and recruit TβRI, enabled it to bind endogenous TβRII but prevented it from binding and recruiting TβRI to form a signaling complex. Such engineered monomers provide a new avenue to probe and manipulate TGF-β signaling and may inform similar modifications of other TGF-β family members.

[1]  A. Bax,et al.  Sparse multidimensional iterative lineshape-enhanced (SMILE) reconstruction of both non-uniformly sampled and conventional NMR data , 2016, Journal of Biomolecular NMR.

[2]  A. Hinck,et al.  Structural Biology and Evolution of the TGF-β Family. , 2016, Cold Spring Harbor perspectives in biology.

[3]  B. Meibohm,et al.  Pharmacokinetics and Pharmacodynamics of Peptide and Protein Drugs , 2016 .

[4]  Woonghee Lee,et al.  NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy , 2014, Bioinform..

[5]  Zhen-ning Wang,et al.  Transforming growth factor-beta1 signaling blockade attenuates gastric cancer cell-induced peritoneal mesothelial cell fibrosis and alleviates peritoneal dissemination both in vitro and in vivo , 2014, Tumor Biology.

[6]  D. Rifkin,et al.  Unchaining the beast; insights from structural and evolutionary studies on TGFβ secretion, sequestration, and activation. , 2013, Cytokine & growth factor reviews.

[7]  G. Mortier,et al.  Bone lessons from Marfan syndrome and related disorders: fibrillin, TGF-B and BMP at the balance of too long and too short. , 2013, Pediatric endocrinology reviews : PER.

[8]  R. Akhurst,et al.  Complexities of TGF-β Targeted Cancer Therapy , 2012, International journal of biological sciences.

[9]  A. Hinck.  Structural studies of the TGF‐βs and their receptors – insights into evolution of the TGF‐β superfamily , 2012, FEBS letters.

[10]  R. Kontermann,et al.  Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives , 2012 .

[11]  B. Meibohm.  Pharmacokinetics and Half-Life of Protein Therapeutics , 2012 .

[12]  J. McPherson,et al.  Antibody targeting of TGF-β in cancer patients. , 2011, Current pharmaceutical biotechnology.

[13]  N. Frangogiannis,et al.  TGF-β signaling in fibrosis , 2011, Growth factors.

[14]  Jennifer L. Lahti,et al.  Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and αvβ3 integrin , 2011, Proceedings of the National Academy of Sciences.

[15]  P. ten Dijke,et al.  Exploring anti-TGF-β therapies in cancer and fibrosis , 2011, Growth factors.

[16]  A. Hinck,et al.  TGF‐β signalling is mediated by two autonomously functioning TβRI:TβRII pairs , 2011, The EMBO journal.

[17]  Owen Johnson,et al.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM , 2011, Acta crystallographica. Section D, Biological crystallography.

[18]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[19]  B. Hann,et al.  Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. , 2011, Cancer research.

[20]  Borries Demeler,et al.  Characterization of reversible associations by sedimentation velocity with UltraScan. , 2010, Macromolecular bioscience.

[21]  M. Reiss,et al.  Targeting the Transforming Growth Factor-β pathway inhibits human basal-like breast cancer metastasis , 2010, Molecular Cancer.

[22]  Borries Demeler,et al.  Methods for the Design and Analysis of Sedimentation Velocity and Sedimentation Equilibrium Experiments with Proteins , 2010, Current protocols in protein science.

[23]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[24]  A. Hinck,et al.  Ternary Complex of Transforming Growth Factor-β1 Reveals Isoform-specific Ligand Recognition and Receptor Recruitment in the Superfamily* , 2010, The Journal of Biological Chemistry.

[25]  Jason Baardsnes,et al.  TbetaR-II discriminates the high- and low-affinity TGF-beta isoforms via two hydrogen-bonded ion pairs. , 2009, Biochemistry.

[26]  G. Corazza,et al.  Transforming growth factor β signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures , 2009, Gut.

[27]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[28]  Borries Demeler,et al.  Modeling analytical ultracentrifugation experiments with an adaptive space-time finite element solution for multicomponent reacting systems. , 2008, Biophysical journal.

[29]  J. Berzofsky,et al.  An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. , 2008, Cancer research.

[30]  A. Hinck,et al.  Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. , 2008, Molecular cell.

[31]  Borries Demeler,et al.  Monte Carlo analysis of sedimentation experiments , 2008 .

[32]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[33]  K. Kuwano,et al.  Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis , 2006, Journal of Clinical Pathology.

[34]  George H. Thomas,et al.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2006 .

[35]  Xiu-fen Lei,et al.  Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. , 2006, Cancer research.

[36]  Gregory De Crescenzo,et al.  Three Key Residues Underlie the Differential Affinity of the TGFβ Isoforms for the TGFβ Type II Receptor , 2006 .

[37]  A. Hinck,et al.  Assembly of TβRI: TβRII:TGFβ ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent , 2005 .

[38]  Jonathan M. Yingling,et al.  Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.

[39]  P. Sun,et al.  Overexpression of human transforming growth factor-beta1 using a recombinant CHO cell expression system. , 2004, Protein expression and purification.

[40]  Juswinder Singh,et al.  Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5). , 2004, Current opinion in drug discovery & development.

[41]  M. Reiss,et al.  Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling. , 2004, Biochemical pharmacology.

[42]  P. Sun,et al.  The 1.1 A crystal structure of human TGF-beta type II receptor ligand binding domain. , 2002, Structure.

[43]  L. Wakefield,et al.  Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. , 2002, The Journal of clinical investigation.

[44]  C. Arteaga,et al.  Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases , 2002 .

[45]  Shashank Deep,et al.  Crystal structure of the human TβR2 ectodomain–TGF-β3 complex , 2002, Nature Structural Biology.

[46]  Quazi Shakey,et al.  Gdf-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding , 2001, Growth factors.

[47]  A. Hinck,et al.  Letter to the Editor: Sequential resonance assignments of the extracellular ligand binding domain of the human TGF-β type II receptor , 2000 .

[48]  Tudor Arvinte,et al.  Conformation and Self-association of Human Recombinant Transforming Growth Factor-β3 in Aqueous Solutions* , 1999, The Journal of Biological Chemistry.

[49]  M. Sporn,et al.  Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. , 1996, Biochemistry.

[50]  M. Grütter,et al.  The crystal structure of TGF‐β3 and comparison to TGF‐β2: Implications for receptor binding , 1996, Protein science : a publication of the Protein Society.

[51]  Anita B. Roberts,et al.  Tumor suppressor activity of the TGF-β pathway in human cancers , 1996 .

[52]  A. Bradley,et al.  Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. , 1996, Molecular endocrinology.

[53]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[54]  M. Sporn,et al.  [Ser77]transforming growth factor-beta 1. Selective biological activity and receptor binding in mink lung epithelial cells. , 1994, The Journal of biological chemistry.

[55]  Jeffrey L. Wrana,et al.  Mechanism of activation of the TGF-β receptor , 1994, Nature.

[56]  M. Wittekind,et al.  HNCACB, a High-Sensitivity 3D NMR Experiment to Correlate Amide-Proton and Nitrogen Resonances with the Alpha- and Beta-Carbon Resonances in Proteins , 1993 .

[57]  Ad Bax,et al.  Amino acid type determination in the sequential assignment procedure of uniformly 13C/15N-enriched proteins , 1993, Journal of biomolecular NMR.

[58]  S. Grzesiek,et al.  Correlation of Backbone Amide and Aliphatic Side-Chain Resonances in 13C/15N-Enriched Proteins by Isotropic Mixing of 13C Magnetization , 1993 .

[59]  Jeffrey L. Wrana,et al.  TGFβ signals through a heteromeric protein kinase receptor complex , 1992, Cell.

[60]  D. Davies,et al.  Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily. , 1992, Science.

[61]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[62]  J. Massagué,et al.  Responsiveness to transforming growth factor-beta (TGF-beta) restored by genetic complementation between cells defective in TGF-beta receptors I and II. , 1991, The Journal of biological chemistry.

[63]  L. Kay,et al.  Backbone dynamics of proteins as studied by 15N inverse detected heteronuclear NMR spectroscopy: application to staphylococcal nuclease. , 1989, Biochemistry.

[64]  A. Hinck,et al.  Production, Isolation, and Structural Analysis of Ligands and Receptors of the TGF-β Superfamily. , 2016, Methods in molecular biology.

[65]  P. Schatz,et al.  Biotinylation of proteins in vivo and in vitro using small peptide tags. , 2000, Methods in enzymology.

[66]  J. Massagué,et al.  TGF- SIGNAL TRANSDUCTION , 1998 .

[67]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[68]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[69]  Vincent B. Chen,et al.  PHENIX: a comprehensive Python-based system for macromolecular structure solution , 2010, Acta crystallographica. Section D, Biological crystallography.